Abemaciclib for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Mar 2022: Trial registered, NCT05288166
  2. 14 Apr 2022: Trial started, NCT05288166

The trials

NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

State
Under way
Phase
Phase 3
People
925 taking part
Started
14 Apr 2022
Primary completion
15 Feb 2024
Arms
Abemaciclib
Results
Posted on the registry
  1. 21 Mar 2022: Trial registered
  2. 14 Apr 2022: Trial started
  3. 27 Jun 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as 3-year abemaciclib without chemo, Verzenio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.